z-logo
open-access-imgOpen Access
Characterization of clinically used oral antiseptics as quadruplex-binding ligands
Author(s) -
David Calabrese,
Katherine Zlotkowski,
Stephanie Alden,
William M. Hewitt,
Colleen M. Connelly,
Robert M. Wilson,
Snehal Gaikwad,
Lu Chen,
Rajarshi Guha,
Craig J. Thomas,
Beverly A. Mock,
John S. Schneekloth
Publication year - 2018
Publication title -
nucleic acids research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 9.008
H-Index - 537
eISSN - 1362-4954
pISSN - 0305-1048
DOI - 10.1093/nar/gky084
Subject(s) - kras , biology , docking (animal) , binding site , chlorhexidine , g quadruplex , surface plasmon resonance , plasma protein binding , computational biology , gene , biochemistry , biophysics , cancer research , dna , mutation , nanotechnology , materials science , medicine , nursing , dentistry , nanoparticle
Approaches to characterize the nucleic acid-binding properties of drugs and druglike small molecules are crucial to understanding the behavior of these compounds in cellular systems. Here, we use a Small Molecule Microarray (SMM) profiling approach to identify the preferential interaction between chlorhexidine, a widely used oral antiseptic, and the G-quadruplex (G4) structure in the KRAS oncogene promoter. The interaction of chlorhexidine and related drugs to the KRAS G4 is evaluated using multiple biophysical methods, including thermal melt, fluorescence titration and surface plasmon resonance (SPR) assays. Chlorhexidine has a specific low micromolar binding interaction with the G4, while related drugs have weaker and/or less specific interactions. Through NMR experiments and docking studies, we propose a plausible binding mode driven by both aromatic stacking and groove binding interactions. Additionally, cancer cell lines harbouring oncogenic mutations in the KRAS gene exhibit increased sensitivity to chlorhexidine. Treatment of breast cancer cells with chlorhexidine decreases KRAS protein levels, while a KRAS gene transiently expressed by a promoter lacking a G4 is not affected. This work confirms that known ligands bind broadly to G4 structures, while other drugs and druglike compounds can have more selective interactions that may be biologically relevant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom